Evidence map›Paper›PMID 34348215›Full record

ArticleEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology2021

Corrigendum to "Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions. [European Neuropsychopharmacology Volume 48, July 2021, Pages 3-31]".

James T McCracken, Evdokia Anagnostou, Celso Arango, Geraldine Dawson, James McPartland, Declan Murphy, Gahan Pandina, Jeremy Veenstra-VanderWeele, ISCTM/ECNP ASD Working Group

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

James T McCrackenDepartment of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, United States. Electronic address: jmccracken@mednet.ucla.edu.
Evdokia AnagnostouDepartment of Pediatrics, University of Toronto, Toronto, Canada.
Celso ArangoDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Univesitario Gregorio Maranon, and School of Medicine, Universidad Complutense de Madrid, CIBERSAM, Madrid, Spain.
Geraldine DawsonDuke University Medical Center, Durham, North Carolina, United States.
James McPartlandYale Child Study Center, New Haven, Connecticut, United States.
Declan MurphyInstitute of Psychiatry, Psychology and Neuroscience, King's College De Crespigny Park, Denmark Hill, London SE5 8AF, United Kingdom.
Gahan PandinaNeuroscience Therapeutic Area, Janssen Research & Development, Pennington, New Jersey, United States.
Jeremy Veenstra-VanderWeeleDepartment of Psychiatry, Columbia University, New York, NY, United States.
ISCTM/ECNP ASD Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34348215

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.